SCHEMBL1692241

SCHEMBL1692241

Cc1ccc2nc(-c3ccccc3Cl)cn2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 13/20 0.59
NPC1 O15118 13/20 0.59
KDM4E B2RXH2 9/20 0.59
ALDH1A1 P00352 6/20 0.59
PKM P14618 5/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
HPGD P15428 3/20 0.59
KMT2A Q03164 2/20 0.59
TP53 P04637 2/20 0.59
HSD17B10 Q99714 2/20 0.59
TSHR P16473 1/20 0.59
CDK5 Q00535 1/20 0.59
CDK5R1 Q15078 1/20 0.59
PAX8 Q06710 2/20 0.56
MEN1 O00255 1/20 0.56
MITF O75030 1/20 0.56
KDM5A P29375 1/20 0.56
KDM5C P41229 1/20 0.56
MAPT P10636 5/20 0.50
APP P05067 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30218497 0.83 RAB9A (0.48) RAB9ANPC1KDM4EALDH1A1PKM
SCHEMBL28615697 0.83 NPC1 (0.58) RAB9ANPC1KDM4EALDH1A1PKM
SCHEMBL1691504 0.81 RAB9A (0.53) RAB9ANPC1KDM4EALDH1A1PKM
SCHEMBL28407317 0.81 NPC1 (0.59) RAB9ANPC1KDM4EALDH1A1PKM
SCHEMBL21708020 0.81 NPC1 (0.59) RAB9ANPC1KDM4EALDH1A1PKM
SCHEMBL28401488 0.81 NPC1 (0.59) RAB9ANPC1KDM4EALDH1A1PKM
SCHEMBL1691344 0.80 RAB9A (0.72) RAB9ANPC1KDM4EALDH1A1PKM
SCHEMBL28407314 0.79 NPC1 (0.58) RAB9ANPC1KDM4EALDH1A1PKM
SCHEMBL2088912 0.77 RAB9A (0.55) RAB9ANPC1KDM4EALDH1A1PKM
SCHEMBL27188298 0.77 RAB9A (0.58) RAB9ANPC1KDM4EALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS BIOVITRUM AB (PUBL) (SE) 2015-08-27 US disclosed
US-20140206662-A1 Imidazopyridine Compounds PROXIMAGEN LTD. (GB) 2014-07-24 US disclosed
EP-2376490-B1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD (GB) 2013-01-23 EP disclosed
US-20120010188-A1 Imidazopyridine Compounds PROMIMAGEN LTD. (GB) 2012-01-12 US disclosed
EP-2376490-A1 IMIDAZOPYRIDINE COMPOUNDS Proximagen Limited (GB) 2011-10-19 EP disclosed
WO-2010064020-A1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD. (GB) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010188-A1 Imidazopyridine Compounds SSB, MIF, IDO1 RAB9A 3798/4885NPC1 1153/4885KDM4E 2671/4885
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS SSB, MIF, IDO1 RAB9A 3798/4885NPC1 1153/4885KDM4E 2671/4885
US-20140206662-A1 Imidazopyridine Compounds SSB, NFKBIA, TPMT RAB9A 3886/4885NPC1 2286/4885KDM4E 2821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.